---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-035948"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:41:28.757003+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports Q3 net loss $104.2M, cuts 40% of workforce, focuses on neurology

## Summary
- Net loss $104.2M ($0.59/share) vs $53.2M ($0.34) year ago; revenue $9.4M down from $26.5M.
- Workforce reduction ~40% (~162 roles); Brisbane HQ to close early 2024; headquarters move to Richmond, CA.
- COO Mark McClung and CSO Jason Fontenot leaving Jan 2, 2024; Amy Pooler and Gregory Davis appointed heads of Research and Technology.
- Cash $132.1M at Sep 30, 2023; expects runway into Q3 2024; non-GAAP opex 2024 ~$115-135M (down ~50%).
- Deferring new investments in Fabry and CAR-Treg programs; seeking partners/investors; Fabry Phase 1/2 data update expected early 2024.

## SEC filing metadata
- accession: 0001628280-23-035948
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023035948/0001628280-23-035948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023035948/sgmo-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-035948
- JSON: https://secwatch.observer/filing/0001628280-23-035948.json
- Plain text: https://secwatch.observer/filing/0001628280-23-035948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.